학술논문

Ceftolozane–tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trial
Document Type
Article
Source
In The Lancet Infectious Diseases December 2019 19(12):1299-1311
Subject
Primary Research
Articles
Language
ISSN
1473-3099